Abstracts Archive - Page 1934 of 2607 - ACR Meeting Abstracts

Abstract Number: 944 • 2015 ACR/ARHP Annual Meeting
Activity of Type I and Type II Interferons in Dermatomyositis Skin Is Correlated with Characteristic Pathologic Features
Hayley W. Leatham¹, Kerri Rieger², Lorinda Chung³, Shufeng Li¹, Brandon W. Higgs⁴, Yihong Yao⁴, Kavita Sarin¹ and David Fiorentino¹, ¹Dermatology, Stanford University, Stanford, CA, ²Dermatopathology, Stanford University, Stanford, CA, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose :Interferon (IFN) signaling is upregulated in dermatomyositis (DM) skin, but the relationship to classic histopathologic features is unknown. Methods :Thirty-nine skin biopsies from patients…
Abstract Number: 945 • 2015 ACR/ARHP Annual Meeting
Anti-Hmgcr Antibodies As Specific Marker for Immune Mediated Necrotizing Myopathies
Lucile Musset¹, Chelsea Bentow², Marvin J. Fritzler³, Jiri Vencovsky⁴, Olivier Benveniste⁵, Ignacio Garcia de la Torre⁶, Franco Franceschini⁷, Katalin Danko⁸, Qinglin Peng⁹, Sophie Hue¹⁰, Olivier Boyer¹¹, Nicola Bizzaro¹², Yoshinao Muro¹³, Xavier Bossuyt¹⁴, Anna Ghirardello¹⁵ and Michael Mahler¹⁶, ¹Immunology, Immunochemistry & Autoimmunity Laboratory, Pitié-Salpêtrière University Hospital, Paris, France, ²Research, Inova Diagnostics, San Diego, CA, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute of Rheumatology, Charles University, Prague, Czech Republic, ⁵Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ⁶Hospital General de Occidente, Zapopan, Mexico, ⁷Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁸Division of Clinical Immunology, 3rd Department of Internal Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary, Co-Author, Debrecen, Hungary, ⁹Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, ¹⁰CHU Henri Mondor, APHP, Créteil, France, ¹¹Immunology, INSERM, U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, Rouen, France, ¹²Laboratory of Clinical Pathology, San Antonio Hospital, Tolmezzo, Italy, ¹³Dermatology, Division of Connective Tissue Disease & Autoimmunity, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹⁴Laboratory Medicine, University Hospitals Leuven, and Department of Microbiology and Immunology, Catholic University of Leuven, Leuven, Belgium, ¹⁵Department of Medicine-DIMED, University of Padova, Padova, Italy, ¹⁶Inova Diagnostics, San Diego, CA
Background/Purpose :Autoantibodies are important biomarkers in the diagnosis of idiopathic inflammatory myopathies (IIM) including polymyositis (PM) and dermatomyositis (DM), inclusion body myositis (IBM) as well…
Abstract Number: 946 • 2015 ACR/ARHP Annual Meeting
Novel Tripartite Motif Proteins Linked to Membrane Integrity As Biomarkers of Dermatomyositis and Polymyositis
Kevin McElhanon¹, Jenna Alloush¹, Nicholas A. Young², Zarife Sahenk³, Rohit Aggarwal⁴, Chester V. Oddis⁵, Wael N. Jarjour² and Noah Weisleder¹, ¹Department of Physiology and Cell Biology, Davis Heart and Lung Research Institute, The Ohio State University College of Medicine, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Neurology, Research Institute at Nationwide Children's Hospital, Columbus, OH, ⁴Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The mechanisms that contribute to the pathogenesis of the idiopathic inflammatory myopathies remains largely unknown. This heterogeneous group of diseases involve autoimmunity toward muscles…
Abstract Number: 947 • 2015 ACR/ARHP Annual Meeting
Cohesin Complex Is a New Myositis Autoantigen
Shin Tanaka¹, S. John Calise², Yurie Satoh³, Yoshiya Tanaka⁴, Monica Vazquez-Del Mercado⁵, Gabriel Medrano-Ramírez⁶, Eric S. Sobel⁷, Westley H. Reeves⁸, Edward K.L. Chan⁹ and Minoru Satoh¹⁰, ¹Human, Information and Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Department of Oral Biology, University of Florida, Miami, FL, ³First Department of Internal Medicine, University of Occupational and Environmental Health, KItakyushu, Japan, ⁴The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan, ⁵Servicio de Reumatología, División de Medicina Interna, Hospital Civil Dr. Juan I. Menchaca, Guadalajara, Mexico, ⁶Rheumatology, Hospital General de Mexico, Secretaria de Salud, Mexico City, Mexico, ⁷Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁸Medicine, University of Florida, Gainesville, FL, ⁹Dept of Oral Biology, University of Florida, Gainesville, FL, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Each myositis specific autoantibodies (MSA) are associated with unique clinical subset and useful biomarkers in polymyositis/dermatomyositis (PM/DM). Identifying new MSA will help in monitoring…
Abstract Number: 948 • 2015 ACR/ARHP Annual Meeting
Autoimmune Myopathies: Effects of Intravenous Immunoglobulin Therapy on Muscle Strength and Predictors of Response
Arash Lahoutiharahdashti¹, Iago Pinal-Fernandez², Jemima Albayda¹, Julie J. Paik³, Sonye K. Danoff⁴, Andrew Mammen⁵ and Lisa Christopher-Stine⁶, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Autoimmune Systemic Diseases Unit, Vall D’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: There is a variable response rate to Intravenous immunoglobulin (IVIG) in patients with autoimmune myopathies. The aim of this study was to determine whether…
Abstract Number: 949 • 2015 ACR/ARHP Annual Meeting
The Metabolic Syndrome, Its Elements and Knee Osteoarthritis: The Framingham Osteoarthritis (OA) Study
Jingbo Niu¹, Mary Clancy², Piran Aliabadi³ and David T. Felson¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology, BUSM, Boston, MA, ³Radiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recent studies have suggested an association between knee OA and the metabolic syndrome (MetS), but in these studies the relationship of this syndrome to…
Abstract Number: 950 • 2015 ACR/ARHP Annual Meeting
In a Two-Year Double-Blind Randomized Controlled Multicenter Study, Chondroitin Sulfate Was Significantly Superior to Celecoxib at Reducing Cartilage Loss with Similar Efficacy at Reducing Disease Symptoms in Knee Osteoarthritis Patients
Jean-Pierre Pelletier¹, Jean Pierre Raynauld², André Beaulieu³, Louis Bessette⁴, Frédéric Morin⁵, Artur J Fernandes⁶, François Abram⁷, Marc Dorais⁸ and Johanne Martel-Pelletier⁹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Osteoarthritis Research Unit, CRCHUM, Montreal, Montreal, QC, Canada, ³Centre de rhumatologie St-Louis, St. Louis, QC, Canada, ⁴Groupe de Recherche en Rhumatologie et Maladies Osseuses, Quebec, Quebec, QC, Canada, ⁵Centre de Recherche Musculo-squelettique, Trois-Rivières, Trois-Rivières, QC, Canada, ⁶Centre de Recherche Musculo-squelettique, Trois-Rivières, 6Rheumatology Division, Sherbrooke, Sherbrooke, QC, Canada, ⁷Medical Imaging Research & Development, ArthroLab Inc, Montreal, QC, Canada, ⁸StatSciences Inc., Montreal, Canada, Montreal, QC, Canada, ⁹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM),, Montreal, QC, Canada
Background/Purpose: In osteoarthritis (OA) treatment, although chondroitin sulfate (CS) was found in a number of studies using radiography to have a structure modifying effect, to…
Abstract Number: 951 • 2015 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tai Chi Versus Physical Therapy in Treating Knee Osteoarthritis: A Randomized, Single-Blind Trial
Chenchen Wang^1,2, Christopher Schmid³, Maura D. Iversen⁴, William F. Harvey², Roger A. Fielding⁵, Jeffrey B. Driban², Lori Lyn Price⁶, John B. Wong^7,8, Kieran Reid⁵, Ramel Rones⁹ and Timothy E. McAlindon², ¹Rheumatology, Tufts Medical Center, Bosotn, MA, ²Rheumatology, Tufts Medical Center, Boston, MA, ³Brown University School of Public Health, Providence, RI, ⁴Northeastern University,, Boston, MA, ⁵Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, ⁶Clinical Care Research, Tufts Medical Center, Boston, MA, ⁷Tufts Medical Center, Boston, MA, ⁸Clinical Decision Making, Tufts Medical Center, Boston, MA, ⁹Center for Mind–Body Therapies, Boston, MA
Background/Purpose: Knee osteoarthritis (OA) causes long-term pain and no effective treatments currently exist. Previous trials demonstrated that Tai Chi can improve both physical and mental…
Abstract Number: 952 • 2015 ACR/ARHP Annual Meeting
Cost-Effectiveness of Opioids for the Treatment of Knee Osteoarthritis: Impact of Chronic Opioid Use on Total Knee Arthroplasty Outcomes
Savannah R. Smith¹, Jeffrey N. Katz², Jamie E. Collins³ and Elena Losina⁴, ¹Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Orthopedics, Brigham and Women's Hospital, BU School of Public Health and Harvard Medical School, Boston, MA
Background/Purpose: The US spends over $1 billion annually on opioids for persons with knee OA. We evaluated whether the use of opioids offers good value…
Abstract Number: 953 • 2015 ACR/ARHP Annual Meeting
Effectiveness of a Progressive Resistence Strength Programme on Hand Osteoarthritis: A Randomized Crontrolled Trial
Michele V. Nery¹, Anamaria Martinez², Fabio Jennings³, Marcelo Souza² and Jamil Natour², ¹Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Federal University of Sao Paulo, Sao Paulo, Brazil, ³Disciplina de reumatologia, Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: Hand osteoarthritis (OA) is highly prevalent, affecting 55-70% of the population over 55 years with an age-related progressive increase. The OA of interphalangeal (IF)…
Abstract Number: 954 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Osteoarthritis and Cardiovascular Disease: Results from a Population-Based Cohort
Lauren King¹, Tetyana Kendzerska^1,2,3 and Gillian Hawker^1,2,3, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
Background/Purpose: Symptomatic osteoarthritis (OA) and cardiovascular disease (CVD) commonly co-exist. Our aim was to determine the extent to which this relationship is explained by common…
Abstract Number: 955 • 2015 ACR/ARHP Annual Meeting
Cancer Risk in 5,108 Patients with Juvenile Idiopathic Arthritis (JIA)
Omid Zahedi Niaki¹, Ann E. Clarke², Rosalind Ramsey-Goldman³, Rae S.M. Yeung⁴, Kristen Hayward⁵, Kiem Oen⁶, Ciarán M. Duffy⁷, Alan M. Rosenberg⁸, Kathleen O'Neil⁹, Emily von Scheven¹⁰, Laura Schanberg¹¹, Jeremy Labrecque¹², Jennifer LF Lee¹³ and Sasha Bernatsky¹⁴, ¹Medicine, McGill University, Montreal, QC, Canada, ²Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Pediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁵Pediatric Rheumatology, University of Washington & SCH, Seattle, WA, ⁶Department of Pediatrics and Child Health, University of Manitoba; Head, Section of Pediatric Rheumatology, Children’s Hospital, University of Manitoba, The Children`s Hospital Foundation of Manitoba, Winnipeg, MB, Canada, ⁷Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁸Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁹Pediatric Rheumatology, RIley Hospital for Children, Indianapolis, IN, ¹⁰Dept of Pediatric Rheumatology, Univ of California San Francisco, San Francisco, CA, ¹¹Pediatrics, Duke Medical Center, Durham, NC, ¹²Clinical Epidemiology, McGill UHC/RVH, Montreal, QC, Canada, ¹³Clinical Epidemiology Rheum, McGill UHC/RVH, Montreal, QC, Canada, ¹⁴Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada
Background/Purpose: Given suspected links between inflammation and malignancy, several groups have attempted to elucidate the baseline risk of cancer in various inflammatory or autoimmune conditions, including rheumatoid arthritis,…
Abstract Number: 956 • 2015 ACR/ARHP Annual Meeting
The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Other Adverse Events
Joost Swart¹, Angela Pistorio², Francesca Bovis³, Ekaterina Alexeeva⁴, Michael Hofer⁵, Susan Nielsen⁶, Jordi Anton⁷, Alessandro Consolaro⁸, Violeta Vladislava Panaviene⁹, Valda Stanevicha¹⁰, Maria Trachana¹¹, Constantin Ailioaie¹², Florence Uettwiller¹³, Fabrizio De Benedetti¹⁴, Elena Tsitsami¹⁵, Berit Flato¹⁶, Pavla Dolezalová¹⁷, Tamás Constantin¹⁸, Troels Herlin¹⁹, Sylvia Kamphuis²⁰, Sujata Sawhney²¹, Despoina Maritsi²², Veronika Vargova²³, Luca Villa⁸, Chiara Pallotti⁸, Angelo Ravelli³, Alberto Martini²⁴, Nico Wulffraat²⁵, Nicolino Ruperto²⁶ and on behalf of for PRINTO, ¹Pediatric Rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Servizio di Epidemiologia e Biostatistica, Istituto Giannina Gaslini, Genoa, Italy, ³Istituto Giannina Gaslini, Genoa, Italy, ⁴Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ⁵Pediatrie, Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁶Pediatric Rheumatology Unit, Juliane Marie Centret, Rigshospitalet, Copenhagen, Denmark, ⁷Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ⁸Pediatria II - Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁹Centre of Pediatrics, Vilnius University, Vilnius, Lithuania, ¹⁰Department of Paediatrics, Riga Stradins University, Riga, Latvia, ¹¹1st Department of Pediatrics, Aristotle University, Thessaloniki, Greece, ¹²II Pediatric Clinic, Private Medical Clinic, IASI, Romania, ¹³Unité d'Immunologie, Hématologie et Rhumatologie Pediatrique, Université Paris-Descartes, IMAGINE Institute, Hôpital Necker-Enfants Malades, Paris, France, ¹⁴Reumatologia, Ospedale Pediatrico Bambino Gesù, Roma, Italy, ¹⁵First Department of Pediatrics, Children Hospital Aghia Sophia, Athens, Greece, ¹⁶Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁷Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ¹⁸Unit of Paediatric Rheumatology, 2nd Dpt of Pediatrics, Semmelweis University, Budapest, Hungary, ¹⁹Department of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark, ²⁰Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²¹Paediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, ²²2nd Department of Academic Pediatrics, Athens Medical School, university of Athens, Athens, Greece, ²³1st Department of Paediatrics and Adolescent Medicine, Šafarik University and Children Faculty Hospital in Košice, Kosice, Slovakia, ²⁴Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy, ²⁵Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²⁶Istituto G. Gaslini, Pediatria II, PRINTO, Genoa, Italy
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA) has greatly changed in the past 15 years thanks to the introduction of biologic agents but little is…
Abstract Number: 957 • 2015 ACR/ARHP Annual Meeting
Double Blind Placebo Controlled Randomized Trial of Probiotics in Enthesitis-Related-Arthritis Category of JIA: Effect on Clinical and Immunological Parameters
Anuj Shukla¹, Priyanka Gaur² and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Gut microflora influences the development and homeostasis of the immune system. Dysbiosis has been reported in various immuno-inflammatory diseases. Pathogenesis of enthesitis-related-arthritis (ERA) category…
Abstract Number: 958 • 2015 ACR/ARHP Annual Meeting
The Time Spent in Inactive Disease before MTX Withdrawal Is Relevant with Regard to the Recurrence of Active Disease in Juvenile Idiopathic Arthritis (JIA) Patients
Jens Klotsche¹, Gerd Ganser², Ivan Foeldvari³, Hans Huppertz⁴, Rolf M. Kuester⁵, Angelika Thon⁶, Kirsten Minden⁷ and Gerd Horneff⁸, ¹Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁴Prof Hess Children’s Hospital, Bremen, Germany, ⁵Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ⁶Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany, ⁷Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁸Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany
Background/Purpose: Methotrexate (MTX) is the most widely used disease modifying antirheumatic drug (DMARD) in JIA and regarded to be a safe drug, effective in around…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].